UroGen Pharma (URGN) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

URGN Stock Forecast


UroGen Pharma stock forecast is as follows: an average price target of $38.60 (represents a 223.55% upside from URGN’s last price of $11.93) and a rating consensus of 'Buy', based on 9 wall street analysts offering a 1-year stock forecast.

URGN Price Target


The average price target for UroGen Pharma (URGN) is $38.60 based on 1-year price targets from 9 Wall Street analysts in the past 3 months, with a price target range of $60.00 to $22.00. This represents a potential 223.55% upside from URGN's last price of $11.93.

URGN Analyst Ratings


Buy

According to 9 Wall Street analysts, UroGen Pharma's rating consensus is 'Buy'. The analyst rating breakdown for URGN stock is 0 'Strong Buy' (0.00%), 7 'Buy' (77.78%), 2 'Hold' (22.22%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

UroGen Pharma Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 14, 2024Jason KolbertEF Hutton$25.00$12.6098.41%109.56%
Jun 14, 2024Stephen RichardsonEvercore ISI$46.00$20.26127.05%285.58%
Jun 14, 2024Leland GershellOppenheimer$40.00$17.50128.57%235.29%
Jun 14, 2024Raghuram SelvarajuH.C. Wainwright$60.00$17.50242.86%402.93%
Jun 14, 2024Paul ChoiGoldman Sachs$22.00$17.5025.71%84.41%
May 14, 2024Leland GershellOppenheimer$32.00$13.07144.84%168.23%
Mar 15, 2024Leland GershellOppenheimer$34.00$14.46135.13%185.00%
Dec 12, 2022-H.C. Wainwright$23.00$7.94189.67%92.79%
Row per page
Go to

The latest UroGen Pharma stock forecast, released on Oct 14, 2024 by Jason Kolbert from EF Hutton, set a price target of $25.00, which represents a 98.41% increase from the stock price at the time of the forecast ($12.60), and a 109.56% increase from URGN last price ($11.93).

UroGen Pharma Price Target by Period


1M3M12M
# Anlaysts117
Avg Price Target$25.00$25.00$37.00
Last Closing Price$11.93$11.93$11.93
Upside/Downside109.56%109.56%210.14%

In the current month, the average price target of UroGen Pharma stock is $25.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 109.56% increase as opposed to UroGen Pharma's last price of $11.93. This month's average price target is down 0.00% compared to last quarter, and down -32.43% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Oct 16, 2024OppenheimerOutperformOutperformHold
Oct 14, 2024EF Hutton-BuyInitialise
Oct 03, 2024H.C. WainwrightBuyBuyHold
Sep 18, 2024OppenheimerOutperformOutperformHold
Aug 22, 2024Guggenheim-BuyInitialise
Aug 16, 2024H.C. WainwrightBuyBuyHold
Jun 14, 2024BenchmarkBuyBuyHold
Jun 14, 2024Keefe, Bruyette & Woods-OutperformUpgrade
Jun 14, 2024StephensEqual-WeightEqual-WeightHold
Jun 14, 2024OppenheimerOutperformOutperformHold
Row per page
Go to

UroGen Pharma's last stock rating was published by Oppenheimer on Oct 16, 2024. The company gave URGN a "Outperform" rating, the same as its previous rate.

UroGen Pharma Financial Forecast


UroGen Pharma Revenue Forecast

Dec 28Sep 28Jun 28Mar 28Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21
Revenue---------------------$20.85M$21.14M$17.19M$18.09M$16.10M$16.60M$13.56M$16.17M$11.35M
Avg Forecast$187.30M$180.09M$180.09M$172.89M$183.65M$176.59M$176.59M$169.52M$101.78M$97.87M$97.87M$93.95M$47.69M$36.36M$31.23M$23.87M$28.24M$24.20M$23.97M$21.39M$22.57M$20.03M$20.12M$17.11M$18.51M$20.15M$17.22M$15.17M$16.24M$15.37M
High Forecast$187.30M$180.09M$180.09M$172.89M$183.65M$176.59M$176.59M$169.52M$101.78M$97.87M$97.87M$93.95M$47.69M$36.36M$31.23M$23.87M$28.24M$24.98M$23.97M$21.39M$23.07M$20.04M$20.12M$17.11M$18.51M$20.15M$17.22M$15.17M$16.24M$15.37M
Low Forecast$187.30M$180.09M$180.09M$172.89M$183.65M$176.59M$176.59M$169.52M$101.78M$97.87M$97.87M$93.95M$47.69M$36.36M$31.23M$23.87M$28.24M$23.42M$23.97M$21.39M$22.06M$20.03M$20.12M$17.11M$18.51M$20.15M$17.22M$15.17M$16.24M$15.37M
# Analysts111122222222111124213111111134
Surprise %---------------------1.04%1.05%1.00%0.98%0.80%0.96%0.89%1.00%0.74%

UroGen Pharma's average Quarter revenue forecast for Dec 23 based on 3 analysts is $22.57M, with a low forecast of $22.06M, and a high forecast of $23.07M. URGN's average Quarter revenue forecast represents a 8.23% increase compared to the company's last Quarter revenue of $20.85M (Sep 23).

UroGen Pharma EBITDA Forecast

Dec 28Sep 28Jun 28Mar 28Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21
# Analysts111122222222111124213111111134
EBITDA---------------------$-12.18M$-15.38M$-20.98M$-19.88M$-17.17M$-18.11M$-21.50M$-27.97M$-29.76M
Avg Forecast$-178.74M$-171.87M$-171.87M$-165.00M$-175.27M$-168.52M$-168.52M$-161.78M$-97.14M$-93.40M$-93.40M$-89.66M$-45.52M$-34.70M$-29.80M$-22.78M$-26.95M$-23.10M$-22.87M$-20.41M$-21.54M$-19.12M$-19.20M$-16.33M$-17.67M$-19.23M$-16.44M$-29.00$-15.50M$-14.66M
High Forecast$-178.74M$-171.87M$-171.87M$-165.00M$-175.27M$-168.52M$-168.52M$-161.78M$-97.14M$-93.40M$-93.40M$-89.66M$-45.52M$-34.70M$-29.80M$-22.78M$-26.95M$-22.36M$-22.87M$-20.41M$-21.06M$-19.12M$-19.20M$-16.33M$-17.67M$-19.23M$-16.44M$-23.00$-15.50M$-14.66M
Low Forecast$-178.74M$-171.87M$-171.87M$-165.00M$-175.27M$-168.52M$-168.52M$-161.78M$-97.14M$-93.40M$-93.40M$-89.66M$-45.52M$-34.70M$-29.80M$-22.78M$-26.95M$-23.84M$-22.87M$-20.41M$-22.02M$-19.12M$-19.20M$-16.33M$-17.67M$-19.23M$-16.44M$-35.00$-15.50M$-14.66M
Surprise %---------------------0.64%0.80%1.28%1.13%0.89%1.10%741482.76%1.80%2.03%

undefined analysts predict URGN's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than UroGen Pharma's previous annual EBITDA (undefined) of $NaN.

UroGen Pharma Net Income Forecast

Dec 28Sep 28Jun 28Mar 28Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21
# Analysts111122222222111124213111111134
Net Income---------------------$-21.88M$-24.14M$-30.21M$-28.25M$-25.83M$-26.69M$-28.39M$-28.45M$-30.21M
Avg Forecast$42.21M$41.44M$42.33M$37.18M$40.49M$39.97M$41.04M$39.14M$20.03M$20.38M$21.67M$19.86M$-17.94M$-25.94M$-28.22M$-32.11M$-28.35M$-30.09M$-30.64M$-31.91M$-25.04M$-31.15M$-41.83M$-48.97M$-39.52M$-42.59M$-46.95M$-30.00$-43.27M$-47.13M
High Forecast$42.21M$41.44M$42.33M$37.18M$40.49M$39.97M$41.04M$39.14M$20.03M$20.38M$21.67M$19.86M$-17.94M$-25.94M$-28.22M$-32.11M$-28.35M$-28.66M$-30.64M$-31.91M$-22.80M$-31.15M$-41.83M$-48.97M$-39.52M$-42.59M$-46.95M$-24.00$-43.27M$-47.13M
Low Forecast$42.21M$41.44M$42.33M$37.18M$40.49M$39.97M$41.04M$39.14M$20.03M$20.38M$21.67M$19.86M$-17.94M$-25.94M$-28.22M$-32.11M$-28.35M$-32.60M$-30.64M$-31.91M$-26.16M$-31.15M$-41.83M$-48.97M$-39.52M$-42.59M$-46.95M$-36.00$-43.27M$-47.13M
Surprise %---------------------0.70%0.58%0.62%0.71%0.61%0.57%946400.00%0.66%0.64%

UroGen Pharma's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. URGN's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

UroGen Pharma SG&A Forecast

Dec 28Sep 28Jun 28Mar 28Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21
# Analysts111122222222111124213111111134
SG&A---------------------$21.75M$22.49M$24.47M$21.63M$19.07M$20.83M$21.30M$87.53M$21.62M
Avg Forecast$125.72B$120.89B$120.89B$116.05B$123.28B$118.54B$118.54B$113.79B$68.32B$65.69B$65.69B$63.07B$32.01B$24.41B$20.96B$16.02B$18.95B$16.25B$16.09B$14.36B$15.15B$13.45B$13.51B$11.49B$12.43B$13.52B$11.56B$22.00$10.90B$10.31B
High Forecast$125.72B$120.89B$120.89B$116.05B$123.28B$118.54B$118.54B$113.79B$68.32B$65.69B$65.69B$63.07B$32.01B$24.41B$20.96B$16.02B$18.95B$16.77B$16.09B$14.36B$15.49B$13.45B$13.51B$11.49B$12.43B$13.52B$11.56B$27.00$10.90B$10.31B
Low Forecast$125.72B$120.89B$120.89B$116.05B$123.28B$118.54B$118.54B$113.79B$68.32B$65.69B$65.69B$63.07B$32.01B$24.41B$20.96B$16.02B$18.95B$15.72B$16.09B$14.36B$14.81B$13.45B$13.51B$11.49B$12.43B$13.52B$11.56B$18.00$10.90B$10.31B
Surprise %---------------------0.00%0.00%0.00%0.00%0.00%0.00%968181.82%0.01%0.00%

UroGen Pharma's average Quarter SG&A projection for Dec 23 is $15.15B, based on 3 Wall Street analysts, with a range of $14.81B to $15.49B. The forecast indicates a 69535.82% rise compared to URGN last annual SG&A of $21.75M (Sep 23).

UroGen Pharma EPS Forecast

Dec 28Sep 28Jun 28Mar 28Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21
# Analysts111122222222111124213111111134
EPS---------------------$-0.68$-1.03$-1.30$-1.22$-1.13$-1.18$-1.25$-1.27$-1.35
Avg Forecast$1.15$1.13$1.15$1.01$1.10$1.09$1.11$1.06$0.54$0.55$0.59$0.54$-0.49$-0.70$-0.77$-0.87$-0.77$-0.82$-0.83$-0.87$-0.68$-0.85$-1.14$-1.33$-1.07$-1.16$-1.27$-1.33$-1.18$-1.28
High Forecast$1.15$1.13$1.15$1.01$1.10$1.09$1.11$1.06$0.54$0.55$0.59$0.54$-0.49$-0.70$-0.77$-0.87$-0.77$-0.78$-0.83$-0.87$-0.62$-0.85$-1.14$-1.33$-1.07$-1.16$-1.27$-1.33$-1.18$-1.28
Low Forecast$1.15$1.13$1.15$1.01$1.10$1.09$1.11$1.06$0.54$0.55$0.59$0.54$-0.49$-0.70$-0.77$-0.87$-0.77$-0.89$-0.83$-0.87$-0.71$-0.85$-1.14$-1.33$-1.07$-1.16$-1.27$-1.33$-1.18$-1.28
Surprise %---------------------0.80%0.91%0.98%1.14%0.98%0.93%0.94%1.08%1.05%

According to undefined Wall Street analysts, UroGen Pharma's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to URGN previous annual EPS of $NaN (undefined).

UroGen Pharma Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
KRONKronos Bio$0.95$7.63703.16%Buy
OVIDOvid Therapeutics$1.18$7.33521.19%Buy
XLOXilio Therapeutics$1.44$7.00386.11%Buy
VACCBarinthus Biotherapeutics$5.00$22.00340.00%-
PEPGPepGen$6.79$29.50334.46%Buy
URGNUroGen Pharma$11.93$38.60223.55%Buy
CMPXCompass Therapeutics$1.70$5.00194.12%Buy
VIGLVigil Neuroscience$3.87$11.00184.24%Buy
PRTCPureTech Health$20.83$57.00173.64%Buy
ELYMEliem Therapeutics$5.11$13.00154.40%Buy
ERASErasca$2.87$7.00143.90%Buy
CCCCC4 Therapeutics$6.45$13.50109.30%Buy
CELCCelcuity$15.36$31.50105.08%Buy
TYRATyra Biosciences$16.42$30.5085.75%Buy
SRRKScholar Rock$27.67$40.0044.56%Buy
EWTXEdgewise Therapeutics$34.48$45.0030.51%Buy
ELVNEnliven Therapeutics$27.65$35.5028.39%Buy
CNTBConnect Biopharma$1.20$1.5025.00%Buy
IKNAIkena Oncology$1.72$1.33-22.67%Buy

URGN Forecast FAQ


Yes, according to 9 Wall Street analysts, UroGen Pharma (URGN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 77.78% of URGN's total ratings.

UroGen Pharma (URGN) average price target is $38.6 with a range of $22 to $60, implying a 223.55% from its last price of $11.93. The data is based on 9 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

According to Wall Street analysts' prediction for URGN stock, the company can go up by 223.55% (from the last price of $11.93 to the average price target of $38.6), up by 402.93% based on the highest stock price target, and up by 84.41% based on the lowest stock price target.

URGN's average twelve months analyst stock price target of $38.6 supports the claim that UroGen Pharma can reach $20 in the near future.

1 Wall Street analyst forecast a $25 price target for UroGen Pharma (URGN) this month, up 109.56% from its last price of $11.93. Compared to the last 3 and 12 months, the average price target increased by 109.56% and increased by 210.14%, respectively.

UroGen Pharma's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $706.35M (high $706.35M, low $706.35M), average EBITDA is $-674M (high $-674M, low $-674M), average net income is $160.64M (high $160.64M, low $160.64M), average SG&A $474.14B (high $474.14B, low $474.14B), and average EPS is $4.36 (high $4.36, low $4.36). URGN's analysts financial forecasts for the fiscal year (Dec 2028) are as follows: average revenue is $720.37M (high $720.37M, low $720.37M), average EBITDA is $-687M (high $-687M, low $-687M), average net income is $163.15M (high $163.15M, low $163.15M), average SG&A $483.55B (high $483.55B, low $483.55B), and average EPS is $4.43 (high $4.43, low $4.43).

Based on UroGen Pharma's last annual report (Dec 2023), the company's revenue was $82.71M, beating the average analysts forecast of $79.83M by 3.61%. Apple's EBITDA was $-65.536M, missing the average prediction of $-76.188M by -13.98%. The company's net income was $-102M, missing the average estimation of $-147M by -30.44%. Apple's SG&A was $93.27M, missing the average forecast of $53.59B by -99.83%. Lastly, the company's EPS was $-0.0035, missing the average prediction of $-3.992 by -99.91%. In terms of the last quarterly report (Sep 2023), UroGen Pharma's revenue was $20.85M, beating the average analysts' forecast of $20.03M by 4.08%. The company's EBITDA was $-12.179M, missing the average prediction of $-19.12M by -36.30%. UroGen Pharma's net income was $-21.879M, missing the average estimation of $-31.151M by -29.77%. The company's SG&A was $21.76M, missing the average forecast of $13.45B by -99.84%. Lastly, the company's EPS was $-0.68, missing the average prediction of $-0.846 by -19.62%